Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/s2...chnologies ) has announced the addition of the "BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030" report to their offering. Several people across the globe suffer from different neurological disorders. However, the drugs currently available in the market provide only symptomatic relief and do not treat the root cause. This is because of their inability to penetrate across the blood brain barrier (BBB). BBB is a highly selective permeable membrane which allows the entry of only specific molecules, across it, into the brain. The widening gap between the demand of effective treatments and supply of BBB permeable drugs is going to provide a major impetus to the BBB market in the coming decade. Several pharma companies have identified the unmet need and have developed proprietary technologies. These technologies cater to the aforementioned concerns and are being deployed to develop drugs and APIs that penetrate across the barrier and reach the brain at therapeutically active amounts. Once approved, these drugs are likely to park a major share of the total market. With growing advances in R&D, and the increasing demands for specific drugs, BBB technologies have become one of the key focus areas of researchers and companies across the world. Several venture capital firms have backed the start-ups working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of this market. Many smaller companies, as a part of their business model, are looking to out-license their technologies to the established players in this industry. The BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030' report provides an extensive study of the emerging market of BBB technologies and associated drugs for neurologic diseases. The focus of this study is primarily on the technologies that are non-invasive in nature. There are other technologies which either disrupt the barrier or use an alternate route to bypass it. These technologies are, for the purpose of this report, considered competing in nature. The report covers various aspects such as research pipeline, technological profiles, recent developments and sales forecast to assess new evolving opportunities. We have also provided a competitive market analysis to compare the potential that resides in the leading neurological indications, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis and brain cancer, for which BBB permeable drugs are being developed. In addition to the well-known technologies, we have also provided case studies on four other technologies; these are either in direct competition or have been previously worked upon. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different technology providers in this industry. One of the key objectives of this report is to understand the future state of the BBB technologies market.
This is done by analyzing the following: - Pipeline candidates based on these technologies - Size of target consumer segments - Expected launch year and countries where these clinical stage candidates are likely to receive commercialization rights - Likely price points Key Topics Covered: 1. Preface 2. Executive Summary 3. Blood Brain Barrier: An Introduction 4. Market Overview 5. Neurological Indications: Market Potential 6. BBB Technologies: Underlying Concepts 7. BBB Technology Profiles 8. Case Studies 9. BBB Technologies: Market Forecasting 10. Interview Transcripts 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List Of Companies Companies Mentioned - Abbott - AbbVie - Accera - Acelot - Acorda - Acyclone Life Sciences - Advanced BioHealing - Aescap Ventures - Affectis Pharmaceuticals - Agate Medical Investments - ALS association - Angiochem - Antea - Aphios - ArmaGen - ArQule - Array BioPharma - Arrowhead Research Corp - Artenga - ASCIL Biopharma - Asebio - Atlas Venture - Aurin Biotech - AZ Therapies - Bach Pharma - Bayer - BBB Therapeutics - BDC Venture Capital - BGN Technologies - Bind Therapeutics - BioAdvance - Bioasis - Biocat - Biocrea - Biogen Idec - Bioline Rx - BioMarin - Biovista - BMS - Boehringer Ingelheim - Boehringer Ingelheim Venture Fund - Boston Scientific - BPI France - BrainsGate - CarThera - CDTI - CEA - Cerecor - Chronos Therapeutics - Cib-Geigy - Cipio Partners - CNRS - Cortice Biosciences - Corvitex - Crinetics - Cyclenium - Dainippon Sumitomo Pharma - Debiopharm - Deciphera - DEKK-TEC - Del Mar Pharma - Drugs Ford - EIP Pharma - Eisai - Elan Pharmaceuticals - Elron Electronic Industries Ltd - Ethris GmbH - Evgen - FerroKinBioSciences - Flocel - Fluorinov Pharma - Fondazione Telethon - Forest Laboratories - Genervon Biopharmaceuticals - Genzyme - GlaxoSmithKline - Global Investment - Heptares - ICB International - Immune Pharmaceuticals - Impax Labs - Impel Neuro Pharma - ImStar - Infinity - INSERM - Iproteos - IRB Barcelona - Janssen - JCR Pharma - Johnson & Johnson - Jonghoud International BV - Kadmon Corporation - KalGene - Krisani Bio - Lixte - Lotus Tissue - Lumena Pharmaceuticals - Lundbeck Pharmaceuticals - Medesis Pharma - MedImmune - Medtronic - Merck - Michael J. Fox Foundation - Minoryx - Mitsui & Co. - MMV financial - Morphotek - Movetis - Mylan - Mystic Pharmaceuticals - nanoLIMIT Therapeutics - Nanomerics - Nativis - Nektar Therapeutics - Neuraltus Pharma - Neuren Pharmaceuticals - NeuroAdjuvants - Neuronix - NeuroSolis - NeuroTransit - NeuroVive - New River - NewGen Therapeutics - NexGenix - Novartis - Novogen - NPS Pharma - Nsgene - OncoNanoBBB - OptiNose - Ortho-McNeil Pharmaceuticals - Oryzon - OSEO - Ossianix - Palobiofarma - ParcCientific - Parke-Davis - Perfusion Technology - Pervasis Therapeutics - Pharmaphenix - Pharmadex - Pharmidex Pharmaceutical Services - Pitango Venture Capital - Plexxikon - Premacure AB - Prexton Therapeutics - Protagenic - ProteoTech - Prothena - Protheragen - PTC Therapeutics - Radius Pharma - Raptor - Repligen - Roche - Sagetis Biotech - SangamoBioSciences - Sanofi - Santaris Pharma - Schering-Plough - Schwarz Pharma - SciFlourLife Sciences - Shire - Siena Biotech - Sihuan - SimPore - SmithKline Beecham - Solvo Biotechnology - Sovicell - Synageva BioPharma Corp - Synageva BioPharma Corp. - Synapse technologies - Tactical Therapeutics - Takeda - Teva - Teva Pharmaceuticals - Transition Therapeutics - Transmolecular Inc. - UCB - UCB Pharma - Vect-Horus - ViroPharma - VistaGen Therapeutics - VoltMed - Xenoport - Zywie For more information visit http://www.researchandmarkets.com/research/s2...chnologies
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Drug Delivery
